laudos.ai
Sign inTry for free

Calculators

15 radiology classifications, one workflow.

Interactive calculators for TI-RADS, BI-RADS, RECIST, Lung-RADS and LI-RADS — and quick reference with official criteria for Bosniak v2019, PI-RADS v2.1, O-RADS, Fleischner 2017, ASPECTS, TLICS, BCLC 2022, C-RADS, McDonald 2017 and Mirels. No login. No clinical data sent server-side. No replacing the physician.

01 / Interactive calculators

Five calculators on dedicated pages.

Each has its own page with embedded calculator, didactic content, FAQ and reviewable references.

02 / Quick reference

Official criteria one click away.

Ten systems with complete criteria. Each card has its own anchor (e.g. #bosniak, #pi-rads) and official reference.

06 / v2019 (CT/MRI)

Bosniak v2019

Kidney

Renal cyst malignancy risk by category, based on wall, septa, calcifications and enhancement on contrast-enhanced CT or MRI.

CategoryMeaning
ISimple cyst — homogeneous, thin wall, no enhancement. Risk < 1%.
IIMinimal thin septations or thin calcifications; no measurable enhancement. Risk ~ 1%.
IIFMultiple thin septations with minimal enhancement; no enhancing nodule. Risk 5%.
IIIThickened/irregular walls or septa with enhancement. Risk ~ 50%.
IVEnhancing nodule or solid cystic mass. Risk > 90%.

When to use

  • CT or MRI with pre/post-contrast phases (incl. nephrographic and excretory)
  • Incidental cystic renal lesion to characterize

Silverman SG et al., Radiology 2019 (Bosniak v2019).

07 / v2.1 (multiparametric MRI)

PI-RADS v2.1

Prostate

Risk of clinically significant prostate cancer per lesion on mpMRI (T2WI + DWI + DCE).

CategoryMeaning
PI-RADS 1Very low — highly unlikely.
PI-RADS 2Low — unlikely.
PI-RADS 3Intermediate (equivocal). Consider PSA + biopsy by context.
PI-RADS 4High — likely.
PI-RADS 5Very high. Targeted biopsy indicated.

When to use

  • Multiparametric prostate MRI pre-biopsy or targeted screening
  • Lesion > 6 mm peripheral or > 4 mm with characteristic DWI/T2

Turkbey B et al., Eur Urol 2019 (PI-RADS v2.1).

08 / v2018 (US) · v2020 (MRI)

O-RADS

Pelvis / adnexal

Malignancy risk in adnexal lesion. US (ovary/adnexa) and MRI (indeterminate mass) versions.

CategoryMeaning
0Incomplete study.
1Normal premenopausal ovary.
2Almost certainly benign (< 1%).
3Low risk (1 – < 10%).
4Intermediate risk (10 – < 50%).
5High risk (≥ 50%).

When to use

  • Transvaginal US with adnexal lesion
  • Pelvic MRI for indeterminate US mass

Andreotti RF et al., Radiology 2020 (O-RADS US/MRI).

09 / 2017 guideline

Fleischner Society 2017

Chest / lung

Incidental pulmonary nodule follow-up on (non-screening) CT. Criteria by solid vs subsolid, size, patient risk.

CategoryMeaning
Solid < 6 mm · low riskNo further follow-up.
Solid < 6 mm · high riskOptional CT at 12 mo.
Solid 6–8 mm · low riskCT at 6–12 mo; consider CT at 18–24 mo.
Solid > 8 mmConsider CT at 3 mo, PET/CT, or biopsy.
Subsolid (GGN) < 6 mmUsually no follow-up.
Subsolid ≥ 6 mm pureCT 6–12 mo, then biennial up to 5 yrs.
Part-solid ≥ 6 mmCT 3–6 mo; persistent/growing → directed workup.

When to use

  • Non-screening chest CT with incidental nodule
  • Do NOT apply to screening — use Lung-RADS

MacMahon H et al., Radiology 2017 (Fleischner).

10 / 10-point scale

ASPECTS

Neuro

Quantifies early ischemic signs in MCA territory on non-contrast CT. Prognostic for thrombolysis/thrombectomy.

CategoryMeaning
10No early ischemic signs — normal territory.
8–9Focal ischemic signs; good functional outcome after reperfusion.
6–7More extensive ischemia; lower reperfusion benefit (multidisciplinary).
≤ 5Extensive hypodensity; worse prognosis, consider thrombectomy contraindication.
0Full MCA-territory involvement.

When to use

  • Non-contrast CT in acute anterior-circulation ischemic stroke
  • Pre-thrombolysis or thrombectomy (DAWN/DEFUSE-3 up to 24 h)

Barber PA et al., Lancet 2000 (ASPECTS).

11 / Score 0–10

TLICS

Spine

Thoracolumbar injury classification summing fracture morphology, PLC integrity and neurologic status — guides surgery.

CategoryMeaning
0–3Conservative treatment.
4Surgeon discretion.
≥ 5Surgical indication.

When to use

  • CT or MRI of thoracolumbar spine post-trauma
  • Pre-operative decision for stabilization

Vaccaro AR et al., Spine 2005 (TLICS).

12 / 2022 update

BCLC

Liver / abdomen

HCC staging and treatment algorithm combining performance status, liver function (Child-Pugh) and tumor features.

CategoryMeaning
Very early (0)Single tumor < 2 cm, Child-Pugh A, PS 0 — resection/ablation.
Early (A)Single ≤ 5 cm or ≤ 3 nodules ≤ 3 cm — resection/ablation/transplant.
Intermediate (B)Multinodular, Child-Pugh A/B, PS 0 — TACE.
Advanced (C)Vascular invasion or extrahepatic — systemic therapy.
Terminal (D)Child-Pugh C or PS > 2 — best supportive care.

When to use

  • Confirmed HCC (LI-RADS LR-5 or biopsy)
  • Multidisciplinary treatment decision

Reig M et al., J Hepatol 2022 (BCLC update).

13 / 2005 / 2020 update

C-RADS

Bowel / colon

Per-lesion + extra-colonic finding category in CT colonography. Two axes: C0–C4 (colon) and E0–E4 (extra-colonic).

CategoryMeaning
C0Inadequate exam.
C1Normal/no lesion > 6 mm. Routine screening.
C2Polyp 6–9 mm (≤ 2). Surveillance/colonoscopy.
C3Polyp ≥ 10 mm or ≥ 3 of 6–9 mm. Colonoscopy.
C4Suspicious for neoplasia — priority referral.

When to use

  • CT colonography
  • Lesion > 6 mm changing management

Zalis ME et al., Radiology 2005 (C-RADS).

14 / 2017 revision

McDonald 2017

Neuro

MS diagnostic criteria based on dissemination in space (DIS) and time (DIT) on MRI, integrated with clinical features.

CategoryMeaning
DISLesions in ≥ 2 of 4 typical regions (periventricular, juxtacortical/cortical, infratentorial, spinal cord).
DITSimultaneous enhancing + non-enhancing lesions OR new T2/enhancing lesion on follow-up MRI.
Definite MSDIS + DIT with compatible clinical picture.
Clinically isolated syndromeSingle episode + DIS — increased MS risk.

When to use

  • Brain MRI in suspected MS or demyelinating syndrome
  • Longitudinal follow-up of diagnosed patient

Thompson AJ et al., Lancet Neurol 2018 (McDonald 2017).

15 / Score 4–12

Mirels Score

Musculoskeletal

Impending pathologic fracture risk in long-bone bone metastasis. Sum of 4 criteria (site, pain, lesion type, relative size).

CategoryMeaning
≤ 7Low risk — radiotherapy/observation.
8Multidisciplinary — consider prophylactic fixation.
≥ 9High risk — surgical indication (prophylactic stabilization).

When to use

  • Long-bone metastasis (femur, humerus) in oncologic patient
  • Decision: prophylactic fixation vs radiotherapy

Mirels H, Clin Orthop Relat Res 1989.

FAQ

Frequently asked.

Do these calculators replace medical judgment?
No. They are educational starting points. The radiologist applies clinical judgment, patient context, service protocol and prior-exam correlation.
Can I paste the result into the report?
Yes. The result is editorially neutral and can be inserted as a conclusion paragraph. Review the category and management before signing — both depend on clinical context.
Are the references current?
Each classification cites its official publication. When a major revision is released (Lung-RADS v2022, Bosniak v2019, BCLC 2022, PI-RADS v2.1), the card follows the latest. Editorial review date is shown on each card.
Do you store what I type?
No. Inputs live in client-component state — never sent to a server, never logged, never used for training.
Lung-RADS vs Fleischner — when to use each?
Lung-RADS is used in organized lung-cancer screening with low-dose CT (USPSTF-eligible patient). Fleischner Society 2017 is the guideline for incidental pulmonary nodules outside screening. Do not mix — management differs.
Is LI-RADS only for cirrhosis?
Applicable to HCC-risk patients: cirrhosis of any etiology, chronic HBV (even without cirrhosis) and prior HCC history. In non-cirrhotic livers outside these contexts, use standard imaging characterization.
Why does TI-RADS vary across services?
Two widely used systems: ACR TI-RADS (point system) and EU-TIRADS (categorical). They are not interchangeable. Standardize one per service.
RECIST 1.1 — only for clinical trials?
No. While the standard for oncology trials, it is widely used in clinical practice for reproducible cross-scan response documentation.

Privacy

Essential cookies keep the site working; analytics only loads with consent.